Exploration by NMR Spectroscopy of the Choline Concentrations in the Insular Cortex of Patients Suffering of Neuropathic Pain Induced by Oxaliplatin

NCT02340403 | Completed

• 2 other identifiers: CHU-02172013-A01588-37
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

Neurotoxic chemotherapy, including oxaliplatin, are responsible for very disabling neuropathic pain that can last for months or even years after the end of chemotherapy. Currently, there is no effective neuroprotective treatment to prevent or relieve this pain. The only strategy is the reduction of oxaliplatin doses or premature discontinuation of therapy, with the risk of burdening the prognosis for remission. Thus, a better understanding of the pathophysiology of these iatrogenic neuropathies appears necessary in order to discover new potential therapeutic targets. Preclinical works were able to demonstrate important metabolic changes in certain brain structures in an animal model of oxaliplatin-induced neuropathy. A significant increase of choline concentration has been found in the posterior insular cortex of neuropathic animals compared with control animals. Furthermore, the concentrations of choline were positively correlated to nociceptive thresholds. Thus, neuropathic pain induced by oxaliplatin would involve the posterior insular cortex and would be associated with an increase in choline concentration at this level. Clinical translation of these preclinical results is feasible in practice since choline concentration can be determined in the brain by non-invasive magnetic resonance spectroscopy.

Conditions

Neuropathy; Painful

Keywords

Neuropathy; Oxaliplatin; Insula; choline

Outcome Measures

Primary Outcomes (1)

• Choline concentration assessed by NMR spectroscopy in the posterior insula

  1 month after chemotherapy end

Secondary Outcomes (10)

• Metabolite concentrations assessed by NMR spectroscopy in the posterior insula

  1 month and 6 months after chemotherapy end

• Pain intensity (VAS and BPI questionnaire)

  1 month and 6 months after chemotherapy end

• Neuropathic pain diagnostic 9DN4 interview questionnaire)

  1 month and 6 months after chemotherapy end

• Neuropathic pain intensity (NPSI questionnaire)

  1 month and 6 months after chemotherapy end

• BPI questionnaire

  1 month and 6 months after chemotherapy end

Study Arms (2)

Oxaliplatin and neuropathic pain

EXPERIMENTAL

The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).

Procedure: NMR Spectroscopy

Oxaliplatin without neuropathic pain

OTHER

The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).

Procedure: NMR Spectroscopy

Interventions

NMR Spectroscopy PROCEDURE

Oxaliplatin and neuropathic pain; Oxaliplatin without neuropathic pain

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Oxaliplatin treated patient and suffering from neuropathic pain
• Chemotherapy (oxaliplatin based) ended
• Pain VAS ≥ 3/10, 1 month after the chemotherapy end
• DN4 interview score ≥ 3/7, 1 month after the chemotherapy end
• Oxaliplatin treated patient without neuropathic pain
• Chemotherapy (oxaliplatin based) ended
• Pain VAS \< 3/10, 1 month after the chemotherapy end
• DN4 interview score \< 3/7, 1 month after the chemotherapy end
• All patients
• right-handed
• No contrindication to MRI
• Free, written and informed consent
• Affiliated to the french health system
• Effective contraception for male or female of childbearing age
• Performance score (WHO) ≤ 2

You may not qualify if:

• Age \< 18
• Left-handed
• BMI \> 30 kg/m²
• Amputees of all or part of an upper limb
• Diabetic patient
• Painful events scheduled after enrollment (eg. surgical resection)
• Neurological diseases (eg Parkinson's disease, stroke, migraine, fibromyalgia ...)
• Chronic pain history before chemotherapy
• Analgesic treatment being other than paracetamol and weak opioids
• Alcohol consumption \>3 units/day (30 g/day) for men and \>2 units/day (20 g/day) for women
• Any unbalanced progressive disease (hepatic failure, renal impairment (creatinine clearance \<30 mL/min), respiratory failure, congestive heart failure, myocardial infarction within the past 6 months ...)
• All active cancer
• Patient with a pacemaker, a cochlear implant, metal implants, or any other magnetic element
• Claustrophobia
• Pregnant or lactation

Sponsors & Collaborators

• University Hospital, Clermont-Ferrand: lead

Study Sites (1)

CHU de Clermont-Ferrand

Clermont-Ferrand, 63003, France

Location

MeSH Terms

Conditions

Pain

Interventions

Magnetic Resonance Spectroscopy

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Spectrum Analysis; Chemistry Techniques, Analytical; Investigative Techniques

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 8, 2015
• First Posted: January 16, 2015
• Study Start: March 9, 2014
• Primary Completion: February 4, 2021
• Study Completion: August 27, 2021
• Last Updated: January 14, 2022

Record last verified: 2021-12

Locations

FR (1)